Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

896 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study.
Koyama T, Shimizu T, Kojima Y, Sudo K, Okuma HS, Shimoi T, Ichikawa H, Kohsaka S, Sadachi R, Hirakawa A, Yoshida A, Ando RM, Ueno T, Yanagaki M, Matsui N, Nakamura K, Yamamoto N, Yonemori K. Koyama T, et al. Among authors: sudo k. Cancer Discov. 2023 Aug 4;13(8):1814-1825. doi: 10.1158/2159-8290.CD-23-0419. Cancer Discov. 2023. PMID: 37369013 Clinical Trial.
Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study.
Iizumi S, Shimomura A, Shimoi T, Sudo K, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. Iizumi S, et al. Among authors: sudo k. Cancer Chemother Pharmacol. 2018 Aug;82(2):275-283. doi: 10.1007/s00280-018-3617-5. Epub 2018 Jun 5. Cancer Chemother Pharmacol. 2018. PMID: 29872875 Free PMC article.
Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population.
Noda-Narita S, Shimomura A, Kawachi A, Sumiyoshi-Okuma H, Sudo K, Shimoi T, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. Noda-Narita S, et al. Among authors: sudo k. Breast Cancer. 2019 Jul;26(4):492-498. doi: 10.1007/s12282-019-00949-4. Epub 2019 Feb 8. Breast Cancer. 2019. PMID: 30737616 Free PMC article.
Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
Inagaki C, Shimoi T, Sumiyoshi Okuma H, Kawachi A, Sudo K, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Arakawa A, Ogawa C, Yoshida A, Fujiwara Y, Tamura K. Inagaki C, et al. Among authors: sudo k. Med Oncol. 2019 May 18;36(7):58. doi: 10.1007/s12032-019-1279-8. Med Oncol. 2019. PMID: 31104192
[Ifosfamide and Paclitaxel for Recurrent or Metastatic Uterine Carcinosarcoma].
Ohtake Y, Sudo K, Kojima Y, Seo T, Okuma H, Nishikawa T, Uno M, Uehara T, Ishikawa M, Tanioka M, Noguchi E, Shimomura A, Yonemori K, Kato T, Fujiwara Y, Tamura K. Ohtake Y, et al. Among authors: sudo k. Gan To Kagaku Ryoho. 2019 Oct;46(10):1525-1529. Gan To Kagaku Ryoho. 2019. PMID: 31631133 Japanese.
HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervix.
Mizuno T, Kojima Y, Yonemori K, Yoshida H, Sugiura Y, Ohtake Y, Okuma HS, Nishikawa T, Tanioka M, Sudo K, Shimomura A, Noguchi E, Kato T, Shimoi T, Uno M, Ishikawa M, Fujiwara Y, Ohe Y, Tamura K. Mizuno T, et al. Among authors: sudo k. Oncol Lett. 2020 Oct;20(4):38. doi: 10.3892/ol.2020.11899. Epub 2020 Jul 23. Oncol Lett. 2020. PMID: 32802162 Free PMC article.
896 results